>Q3 2024 results below expectations on orders/revenue, above on profitability - This morning, Jenoptik reported Q3 2024 results which were below expectations on orders/revenue, but above on profitability. Revenues were € 274.3m, below the company-compiled consensus at € 279.4m. EBITDA was € 59.1m giving a margin of 21.5%, above the consensus at €56.2m and 20.1%. EBIT came in at € 40.9m, i.e. a margin of 14.9%, above the consensus at € 37.8m and 13.5%. EPS was € 0.46, ...
>Q3 2024 results below expectations on orders/revenue, above on profitability - This morning, Jenoptik reported Q3 2024 results which were below expectations on orders/revenue, but above on profitability. Revenues were € 274.3m, below the company-compiled consensus at € 279.4m. EBITDA was € 59.1m giving a margin of 21.5%, above the consensus at €56.2m and 20.1%. EBIT came in at € 40.9m, i.e. a margin of 14.9%, above the consensus at € 37.8m and 13.5%. EPS was € 0.46, ...
Notre scénario central s’est concrétisé dans la nuit : Donald Trump remporte la présidentielle américaine, et le choix des électeurs ne devrait pas être contesté. Il pourrait disposer d’une majorité dans les deux assemblées. Les actions américaines en seront les premières bénéficiaires. Sur les actions européennes, les secteurs les plus gagnants seront l’Energie, les Médias, les Métaux, Construction & Materials, Financial Services, Insurance. Sont en revanche plus à risque Utilities, ...
Our baseline scenario materialised last night: Donald Trump seems to be on course to win the US presidential election, and the choice of the electorate is unlikely to be challenged. He could end up with a majority in both houses of Congress. US equities will be the first to benefit from this development. In European equities, the biggest winners will be Energy, Media, Metals, Construction & Materials, Financial Services and Insurance. More at risk, however, are the Utilities, Spirits,...
>2025 guidance pushed out to 2026 due to slower than expected recovery in the semiconductor equipment industry - Jenoptik yesterday evening warned that its 2025 revenue guidance of € 1.2bn and EBITDA margin target of between 21% and 22% were pushed out by one year and are now set to be achieved in 2026, due to the slower-than-expected cyclical upturn in the semiconductor equipment sector. The group has not given detailed guidance for 2025 given the uncertainty. As we ...
>Les objectifs 2025 ont été reportés pour 2026 en raison d’une reprise plus lente que prévu dans l’industrie des équipementiers semiconducteurs - Jenoptik a averti hier soir que ses objectifs 2025 de CA de 1.2 Md€ et d’une marge d’EBITDA comprise entre 21% et 22% étaient reportés d’un an et devraient désormais être atteints en 2026, en raison d’une reprise cyclique plus lente que prévu des équipementiers semiconducteurs. Le groupe n’a pas donné de guidance précise pou...
>Rating upgraded from Neutral to Outperform, even though we adjust our target price to € 30 vs € 32 - Jenoptik will report its Q3 2024 results on 12/11 before the start of trading. The operating performance in Q3 2024 should not produce any surprises. On the other hand, we will pay close attention to comments on orders intake for the next quarters and estimates for 2025. The warning from ASML, the group’s biggest customer (~20% of sales), could affect orders in Advanc...
>Opinion relevée de Neutre à Surperformance, même si nous ajustons notre OC à 30 € vs 32 € - Jenoptik publiera ses résultats T3 24 le 12/11 avant l’ouverture. La performance opérationnelle du T3 24 devrait être sans surprises. Nous serons, en revanche, très attentifs aux commentaires sur l’évolution future des commandes et les prévisions sur 2025. En effet, l’avertissement d’ASML, son principal client (~20% du CA), pourrait impacter les commandes de l’activité ‘Advanc...
>A fresh acceleration to worldwide semiconductor sales in August at +20.6% y-o-y (vs +18.7% in July) - Worldwide semiconductor sales in August 2024 were published by the WSTS (World Semiconductor Trade Statistics) with the usual one-month lag. On a three-month moving average, sales came to $ 53.1bn, ahead of our forecast of $ 52bn. This represents a sequential increase of 3.5% and +20.6% y-o-y, after +18.7% in July. At the regional level, sales from one year to the n...
>Nouvelle accélération de la croissance des ventes mondiales de semis en août à +20.6% yoy (vs +18.7% en juillet) - Les ventes mondiales de semiconducteurs d’août 2024 ont été publiées par WSTS (World Semiconductor Trade Statistics), avec (comme toujours) un mois de décalage. En données lissées (moyenne de 3 mois), elles ressortent à 53.1 Md$ au-dessus de notre prévision à 52 Md$. Il s’agit d’une hausse séquentielle de 3.5% et annuelle de 20.6% après 18.7% en juillet....
Last week we held our fourth ODDO BHF Iberian Forum. The event was fully virtual and took place on October 1 and 2. With 62 Iberian issuers, close to 200 institutional investors and c. 800 meetings, this is one of the largest dedicated Iberian conferences held this year. This note brings together 49 feedback documents, with 5 target price revisions (o/w 3 downward revisions) and a rating downgrade on Pharma Mar. The main subjects of debate were i/ the trend in final demand in the con...
Last week we held our fourth ODDO BHF Iberian Forum. The event was fully virtual and took place on October 1 and 2. With 62 Iberian issuers, close to 200 institutional investors and c. 800 meetings, this is one of the largest dedicated Iberian conferences held this year. This note brings together 49 feedback documents, with 5 target price revisions (o/w 3 downward revisions) and a rating downgrade on Pharma Mar. The main subjects of debate were i/ the trend in final demand in the con...
Last week we held our fourth ODDO BHF Iberian Forum. The event was fully virtual and took place on October 1 and 2. With 62 Iberian issuers, close to 200 institutional investors and c. 800 meetings, this is one of the largest dedicated Iberian conferences held this year. This note brings together 49 feedback documents, with 5 target price revisions (o/w 3 downward revisions) and a rating downgrade on Pharma Mar. The main subjects of debate were i/ the trend in final demand in the con...
Last week we held our fourth ODDO BHF Iberian Forum. The event was fully virtual and took place on October 1 and 2. With 62 Iberian issuers, close to 200 institutional investors and c. 800 meetings, this is one of the largest dedicated Iberian conferences held this year. This note brings together 49 feedback documents, with 5 target price revisions (o/w 3 downward revisions) and a rating downgrade on Pharma Mar. The main subjects of debate were i/ the trend in final demand in the con...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.